Washington, DC (March 7, 2025) – Following Dr. Marty Makary’s confirmation hearing for Food and Drug Administration (FDA) commissioner, the Pharmaceutical Printed Literature Association (PPLA) is urging Dr. Makary to protect Americans’ health and safety with printed medication information once confirmed.
Dr. Makary could reverse many harmful regulations that were initiated under the Biden administration. The FDA previously proposed two dangerous rules that threaten access to life-saving printed medication information. One would eliminate printed Prescribing Information (PI), which is vital for pharmacists to counsel patients, while the other would reduce access to printed Patient Medication Information (PMI), the guidance attached to prescriptions detailing a drug’s purpose, instructions for use, and potential side effects that patients need to take their prescriptions correctly.
“Following Dr. Marty Makary’s confirmation hearing for FDA commissioner, PPLA urges him to protect pharmacy care and patient safety by rescinding the FDA’s proposed regulations on PI and PMI once he is confirmed,” said Dave Joesten, Board Chairman of PPLA. “The proposed rules would limit access to information that helps pharmacists take care of patients and empowers patients to take care of themselves. We hope that Dr. Makary rescinds these rules once he is confirmed and saves lives.”
The Pharmaceutical Printed Literature Association
Chartered in 2001, the PPLA serves as the voice for our members, advocating for patient safety and risk communication by fighting to keep information on paper and readily accessible for patients and caregivers. This information helps drive the patient involvement model of health care, helping patients get the maximum benefits from the powerful drugs they take while minimizing risk.
For more information about PPLA, click here.